JPMorgan Chase & Co. Issues Positive Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price

Bausch + Lomb (NYSE:BLCO) had its target price boosted by equities researchers at JPMorgan Chase & Co. from $16.00 to $22.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 7.97% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $20.00 price target on shares of Bausch + Lomb in a research note on Thursday. Royal Bank Of Canada upped their price objective on shares of Bausch + Lomb from $21.00 to $23.00 and gave the company an “outperform” rating in a report on Thursday. Weiss Ratings upgraded shares of Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 21st. Evercore set a $17.00 target price on shares of Bausch + Lomb in a research note on Monday, July 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Bausch + Lomb in a research report on Friday, August 28th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $20.62.

Bausch + Lomb Stock Down 0.1%

Shares of NYSE BLCO traded down $0.02 during trading on Thursday, hitting $20.38. The stock had a trading volume of 3,425,082 shares, compared to its average volume of 465,881. Bausch + Lomb has a 12 month low of $14.44 and a 12 month high of $21.36. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.55 and a quick ratio of 1.02. The company has a market capitalization of $7.28 billion, a PE ratio of -42.45, a PEG ratio of 0.55 and a beta of 0.56. The firm has a fifty day moving average of $17.24 and a two-hundred day moving average of $16.66.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, October 28th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.13. The business had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a positive return on equity of 4.14% and a negative net margin of 3.21%. Bausch + Lomb’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the company posted $0.18 earnings per share. As a group, equities research analysts forecast that Bausch + Lomb will post 0.81 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Eschenbach Andrew C. Von sold 12,500 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $16.50, for a total value of $206,250.00. Following the transaction, the director owned 69,792 shares of the company’s stock, valued at approximately $1,151,568. This represents a 15.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Frederick Munsch sold 52,900 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $16.78, for a total value of $887,662.00. Following the completion of the sale, the chief accounting officer owned 45,831 shares in the company, valued at $769,044.18. This trade represents a 53.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 71,459 shares of company stock valued at $1,194,370 over the last 90 days. Company insiders own 1.45% of the company’s stock.

Institutional Trading of Bausch + Lomb

A number of large investors have recently modified their holdings of the business. Beach Point Capital Management LP acquired a new stake in shares of Bausch + Lomb during the 3rd quarter valued at approximately $5,882,000. Whitebox Advisors LLC lifted its stake in Bausch + Lomb by 15.8% during the first quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock worth $17,519,000 after purchasing an additional 150,641 shares during the last quarter. Engineers Gate Manager LP acquired a new position in Bausch + Lomb in the second quarter worth $1,479,000. Sei Investments Co. boosted its holdings in Bausch + Lomb by 100.0% in the first quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock worth $2,214,000 after purchasing an additional 69,633 shares during the period. Finally, Counterpoint Mutual Funds LLC bought a new stake in Bausch + Lomb during the third quarter valued at $670,000. Institutional investors own 11.07% of the company’s stock.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Q3 results exceeded expectations: Adjusted EPS was $0.34 versus the $0.21 consensus estimate and $0.18 a year earlier. Revenue increased approximately 7.3% year over year to about $1.38 billion, slightly ahead of the $1.37 billion estimate. Bausch + Lomb Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: 2026 outlook was raised: Bausch + Lomb now expects full-year revenue of $5.450 billion to $5.550 billion and adjusted EBITDA of $1.090 billion to $1.140 billion. Management cited continued momentum from its Vision ’27 strategy and strong growth across its eye-care businesses. Bausch + Lomb Raises 2026 Guidance
• Positive Sentiment: RBC became more bullish: RBC raised its price target to $23 from $21 while maintaining an Outperform rating, indicating greater confidence in the company’s earnings momentum and longer-term growth prospects. RBC Raises Price Target
• Neutral Sentiment: Analyst views remain mixed: Deutsche Bank raised its target to $20 from $16 but retained a Hold rating. Wells Fargo increased its target to $19 from $18 while keeping an Equal Weight rating, suggesting limited upside at recent trading levels.
• Neutral Sentiment: The earnings improvement is encouraging, but Bausch + Lomb still reported a negative net margin, so investors may continue to focus on profitability, cash flow and execution of the company’s growth plan.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.